Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Max-3 by MaxiNovel Pharmaceuticals for Alopecia Areata: Likelihood of Approval
Max-3 is under clinical development by MaxiNovel Pharmaceuticals and currently in Phase I for Alopecia Areata. According to GlobalData, Phase...